This podcast features an interview with David Ricks, CEO of Eli Lilly, focusing on the company's GLP-1 weight-loss drugs and their unexpected applications. The conversation covers the drug's discovery, its effectiveness in treating various conditions (including potential benefits for alcoholism and Alzheimer's), and the challenges of drug development and pricing. Ricks details Eli Lilly's strategies for accelerating drug discovery, emphasizing parallel processing and efficient decision-making. He also discusses the company's approach to pricing, balancing profitability with ethical considerations and societal impact, citing the eventual affordability of generic drugs as a key benefit. The interview concludes with Ricks sharing his personal approach to leadership and advice for young people.
